About the Company
We do not have any company description for Seres Therapeutics, Inc. at the moment.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $MCRB News
Seres Therapeutics gets grant for composition of isolated bacteria in capsule for dysbiosis treatment
Discover the groundbreaking patent by Seres Therapeutics Inc for a unique composition targeting dysbiosis in mammals. Learn how specific bacterial species in a capsule can inhibit pathogenic bacteria ...
MCRB Seres Therapeutics, Inc.
Seres Therapeutics, Inc., a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that ...
Seres Therapeutics Announces 2024 Virtual Stockholders Meeting
Seres Therapeutics (MCRB) has released an update. The Board of Directors of Seres Therapeutics, Inc. has scheduled the ...
Seres Therapeutics Announces Completion of Patient Enrollment for SER-155 Phase 1B Cohort 2 Clinical Trial in Allogenic HSCT
April 09, 2024--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, announced today that enrollment is complete in the placebo-controlled Cohort 2 ...
Increases to Seres Therapeutics, Inc.'s (NASDAQ:MCRB) CEO Compensation Might Cool off for now
our data shows that Seres Therapeutics, Inc. has a market capitalization of US$118m, and reported total annual CEO compensation of US$3.2m for the year to December 2023. Notably, that's a decrease ...
Increases to Seres Therapeutics, Inc.'s (NASDAQ:MCRB) CEO Compensation Might Cool off for now
Check out our latest analysis for Seres Therapeutics At the time of writing, our data shows that Seres Therapeutics, Inc. has a market capitalization of US$118m, and reported total annual CEO ...
Seres Therapeutics Inc MCRB
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Seres Therapeutics Inc (MCRB)
On Wednesday, Oppenheimer adjusted its stock price target for Seres Therapeutics (NASDAQ:MCRB), a microbiome therapeutics platform company, reducing it to $5.00 from the previous ...
Seres Therapeutics Inc (MCRB)
As of late, it has definitely been a great time to be an investor in Seres Therapeutics, Inc. (NASDAQ:MCRB) . The stock has moved higher by 15.2% in the past month ...
Loading the latest forecasts...